Arvinas

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.

About ARVN

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.

CEO

John G. Houston

CEOJohn G. Houston

Employees

430

Employees430

Headquarters

New Haven, Connecticut

HeadquartersNew Haven, Connecticut

Founded

2013

Founded2013

Employees

430

Employees430

ARVN Key Statistics

Market cap

697.83M

Market cap697.83M

Price-Earnings ratio

-1.87

Price-Earnings ratio-1.87

Dividend yield

—

Dividend yield—

Average volume

2.65M

Average volume2.65M

High today

$9.64

High today$9.64

Low today

$9.39

Low today$9.39

Open price

$9.57

Open price$9.57

Volume

1.06M

Volume1.06M

52 Week high

$29.61

52 Week high$29.61

52 Week low

$5.90

52 Week low$5.90

ARVN News

TipRanks 24h

Arvinas’ ARV-393: A New Hope in Non-Hodgkin’s Lymphoma Treatment?

Arvinas Holding Company ((ARVN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 5...

TipRanks 4d

Arvinas Unveils Promising Preclinical Data for ARV-806

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

TipRanks 4d

Arvinas presents preclinical data for ARV-806

Arvinas (ARVN) announced preclinical data for ARV-806, a PROTAC KRAS G12D degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and...

Analyst ratings

50%

of 18 ratings

Buy

44.4%

Hold

50%

Sell

5.6%

People also own

Based on the portfolios of people who own ARVN. This list is generated using Robinhood data, and it’s not a recommendation.